The Early Access Committee on which Malecare sits has been successful in adding an additional site in Long Island, New York to the Early Access Trial of Radium-233 Chloride (Alpharedin) for men with advanced prostate cancer who are castrate resistant and have at least two (2) bone metastases.

If you are interested in this trial contact:

North Shore Long Island Medical Ctr
New Hyde Park, NY 11040
Contact: Kerry Ann Brown or (718) 470-4642

To learn more about this early access trial go to:

To learn more about Radium-233 Chloride (Alpharadin) go to:

Joel T. Nowak, M.A., M.S.W.